Monopar Therapeutics (MNPR) Gains from Investment Securities (2018 - 2025)
Monopar Therapeutics' (MNPR) quarterly Gains from Investment Securities came in at -$127342.0 in Q4 2025, down 290.22% year-on-year from $66946.0 in Q4 2024, and down 151.27% quarter-over-quarter from $248381.0 in Q3 2025.
Monopar Therapeutics (MNPR) Gains from Investment Securities (2018 - 2025) Analysis & Trends
Monopar Therapeutics has disclosed Gains from Investment Securities across 8 years of filings, most recently posting -$127342.0 for Q4 2025.
- Gains from Investment Securities for Q4 2025 came in at -$127342.0, down 290.22% year-over-year; the trailing twelve-month figure through Dec 2025 was -$70800.0 (down 225.22% YoY), and the FY2025 annual result was $616555.0, up 43.75% from the prior year.
- Gains from Investment Securities came in at -$127342.0 for Q4 2025 at Monopar Therapeutics, down from $248381.0 in the prior quarter.
- In the past five years, Gains from Investment Securities ranged from a high of $2.1 million in Q1 2023 to a low of -$127342.0 in Q4 2025.
- The 5-year median for Gains from Investment Securities is $96871.5 (2021), against an average of $529340.1.
- Across the five-year window, Gains from Investment Securities jumped 1157.91% in 2024 and slumped 290.22% in 2025, its largest moves.
- Monopar Therapeutics' Gains from Investment Securities stood at $115151.0 in 2021, then slumped by 113.66% to -$15726.0 in 2022, then surged by 133.84% to $5322.0 in 2023, then surged by 1157.91% to $66946.0 in 2024, then plunged by 290.22% to -$127342.0 in 2025.
- The last three Gains from Investment Securities figures came in at -$127342.0 (Q4 2025), $248381.0 (Q3 2025), and $23527.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - |
| 10 | Monopar Therapeutics | 441.25 Mn | 441.25 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -127,342.00 |
| Dec 31, 2025 | -127,342.00 |
| Sep 30, 2025 | 248,381.00 |
| Sep 30, 2025 | 248,381.00 |
| Jun 30, 2025 | 23,527.00 |
| Jun 30, 2025 | 23,527.00 |
| Mar 31, 2025 | 216,331.00 |
| Mar 31, 2025 | 216,331.00 |
| Dec 31, 2024 | 66,946.00 |
| Dec 31, 2024 | 66,946.00 |
| Sep 30, 2024 | 43,523.00 |
| Sep 30, 2024 | 43,523.00 |
| Jun 30, 2024 | 78,592.00 |
| Jun 30, 2024 | 78,592.00 |
| Dec 31, 2023 | 5,322.00 |
| Dec 31, 2023 | 5,322.00 |
| Sep 30, 2023 | 42,851.00 |
| Sep 30, 2023 | 42,851.00 |
| Mar 31, 2023 | 2.15 Mn |
| Mar 31, 2023 | 2.15 Mn |